The costs of a multiple sclerosis relapse in Catalonia (Spain);¿Cuánto cuesta un brote de esclerosis múltiple en Cataluña?

Neurologia

Volumn 21, Issue 7, 2006, Pages 341-347

  Casado, Virginia ^a   Martinez Yelamos S ^a   Martinez Yelamos A ^b   Carmona, O ^c   Alonso, L ^a   Romero, L ^a   Moral, E ^a   Arbizu, T ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL DE VILADECANS   (Spain)

^c HOSPITAL DE FIGUERES   (Spain)

Author keywords

Catalonia; Costs; Multiple sclerosis; Relapse

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; COST OF ILLNESS; ECONOMIC ASPECT; FEMALE; HEALTH CARE MANAGEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; QUALITY OF LIFE; QUESTIONNAIRE; RECURRENT DISEASE; SPAIN;

ADULT; COST OF ILLNESS; DISEASE PROGRESSION; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; QUALITY OF LIFE; QUESTIONNAIRES; SPAIN;

EID: 33749684663     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Amatto MP, Battaglia MA, Caputo D, Fattore G, Gerzelli S, Pittaro M, et al. The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J Neurol 2002;249:152-63.
2. Asche CV, Ho E, Chan B, Coyte PC. Economic consequences of multiple sclerosis for Canadians. Acta Neurol Scand 1997; 95:268-74.
3. Blumhardt LD, Wood C. The economics of MS: a cost of illness study. Br J Med Econ 1996;10:99-118.
4. Brown MG, Murray TJ, Fisk JD. A therapeutic and economic assessment of interferon beta in multiple sclerosis. Halifax: Dalhousie Multiple Sclerosis Research Unit, 1996.
5. Casado V, Martínez-Yélamos S, Martínez- Yélamos A, Carmona O, Hernández JJ, Arbizu T. A relapse of multiple sclerosis: how much does it cost in Catalonia? Mult Scler 2002;8 (Suppl. 1):301.
6. Grima DT, Torrance GW, Francis G, Rice G, Rosner AJ, Lafortune L. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler 2000;6:91-8.
7. Grudzinski AN, Hakim Z, Cox ER, Bootman JL. The economics of multiple sclerosis, distribution of costs and relationship to disease severity. Pharmacoeconomics 1999;15:229-40.
8. Hauser SL. Multiple sclerosis and other demyelinating diseases. En: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, editores. Harrison's principles of internal medicine. Toronto: McGraw Hill Inc., 1994; p. 2281-94.
9. Henriksson F, Fredrikson S, Masterman T, Jönson B. Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neurol 2001; 8: 27-35.
10. Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to assessment practices and procedures. Milbank Memorial Fund Quarterly/Health Soc 1982;60:429-91.
11. Hodgson TA. Cost of illness in cost-effectiveness analysis, a review of the methodology. Pharmacoeconomics 1994;6:536-52.
12. Kobelt G, Jönson L, Henriksson F, Fredrikson S, Jönson B. Cost-utility analysis of interferon beta 1b in secondary progressive multiple sclerosis. Int J Technol Assess Health Care 2000;16:768-80.
13. Kobelt G, Jönson L, Miltenburger C, Jönson B. Cost-utility of interferon beta 1b in secondary progressive multiple sclerosis, using natural history data. Int J Technol Assess Health Care 2002;18:127-38.
14. Kobelt G, Jönson L, Fredrikson S. Cost-utility of interferon beta 1b in the treatment of patients with active relapsing-remitting or secondary multiple sclerosis. Eur J Health Econom 2003;4:50-9.
15. Kobelt G, Lindgren P, Parkin D. Costs and quality of life in multiple sclerosis. An observational study in Germany. HEPAC 2001; 2:60-8.
16. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998;13:1-7.
17. Martinez-Yélamos S, Casado V, Carmona O, Martinez-Yélamos A, Ramón JM, Arbizu T. Prognosis in relapsing-remitting multiple sclerosis. A hierarchical model. Mult Scler 2002;8 (Suppl. 1):215.
18. Midgard R, Rüse T, Nyland H. Impairment, disability and handicap in multiple sclerosis, a cross sectional study in an incident cohort in More and Romsdal County, Norway. J Neurol 1996; 243:337-44.
19. Moral E, Carmona O, Casado V. Estudio de la incidencia de la esclerosis multiple en la region sanitaria de Costa de Ponent durante 15 años consecutivos. Neurología 2002;17:494-597.
20. Murphy N, Confavreux C, Haas J, Köning N, Roullet E, Sailer M, et al, and the Cost of Multiple Sclerosis Study Group. Economic evaluation of multiple sclerosis in the UK, Germany and France. Pharmacoeconomics 1998;13:607-22.
21. O'Brien JA, Ward AJ, Patrick AR, Caro J. Costs of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003;3:17.
22. Parkin D, Jacoby A, McNamee P, Miller P, Thomas S, Bares D. Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg Psychiatry 2000;68:144-9.
23. Pittock SJ. Change in MS-related disability in a population-based cohort, a 10-year follow-up study. Neurology 2004;62:51-9.
24. The Canadian Burden of Illness Study Group. Burden of Illness of multiple sclerosis, part I: Cost of Illness, and part II: Quality of life. Can J Neurol Sci 1998;25:23-37.
25. Tola MA, Yugueros MA, Fernández-Buey N, Fernández-Herranz R. Prevalence of multiple sclerosis in Valladolid, northern Spain. J Neurol 1999;246:170-4.
26. Torrance GW, Feeny DH, Furlong WJ, Barr RD, Zhang Y, Wang Q. Multiattribute utility function for a comprehensive health status classification system. Health Utility Mark 2. Med Care 1996; 34:702-22.